Exousia Bio (LMMY) Liabilities and Shareholders Equity (2023 - 2025)
Lamy (LMMY) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $22.1 million as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 88620.81% to $22.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.1 million through Nov 2025, up 20468.31% year-over-year, with the annual reading at $27453.0 for FY2024, 25.89% down from the prior year.
- Liabilities and Shareholders Equity hit $22.1 million in Q4 2025 for Lamy, up from $24854.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.1 million in Q4 2025 to a low of $24854.0 in Q4 2024.
- Historically, Liabilities and Shareholders Equity has averaged $2.5 million across 3 years, with a median of $27453.0 in 2024.
- Biggest five-year swings in Liabilities and Shareholders Equity: dropped 27.24% in 2024 and later skyrocketed 88620.81% in 2025.
- Year by year, Liabilities and Shareholders Equity stood at $26742.0 in 2023, then dropped by 7.06% to $24854.0 in 2024, then surged by 88620.81% to $22.1 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for LMMY at $22.1 million in Q4 2025, $24854.0 in Q4 2024, and $27958.0 in Q3 2024.